N-methylbenzamide hydrochloride | 74973-82-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-methylbenzamide hydrochloride
• 英文别名: N-methylbenzamide;hydrochloride
• CAS: 74973-82-3
• 化学式: C₈H₉NO*ClH
• 分子量: 171.626
• InChiKey: DQLNWHBKIKNFCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.47
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  29.1
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• [EN] NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES<br/>[FR] NOUVELLES IMIDAZO[1,5-A]PYRIDINES SUBSTITUÉES EN POSITION 5 OU 8 EN TANT QU'INDOLEAMINE ET/OU TRYPTOPHANE 2,3-DIOXYGÉNASES
  申请人：BEIGENE LTD

  公开号：WO2018054365A1

  公开（公告）日：2018-03-29

  Disclosed herein are 5 or 8-substituted imidazo [1, 5-a] pyridines and pharmaceutical compositions comprising at least one such 5 or 8-substituted imidazo [1, 5-a] pyridines, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain 5 or 8-substituted imidazo [1, 5-a] pyridines that can be useful for inhibiting indoleamine 2, 3-dioxygenase and/or tryptophane 2, 3-dioxygenase and for treating diseases or disorders mediated thereby.

  本文披露了5或8-取代咪唑[1,5-a]吡啶和包含至少一种此类5或8-取代咪唑[1,5-a]吡啶的药物组合物，其制备方法以及在治疗中的用途。本文披露了某些5或8-取代咪唑[1,5-a]吡啶，可用于抑制吲哚胺2,3-二氧化酶和/或色氨酸2,3-二氧化酶，并用于治疗由此介导的疾病或疾病。
• [EN] TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS<br/>[FR] ANTAGONISTES DE TYPE PYRIDAZINE TÉTRASUBSTITUÉE DE LA VOIE DE SIGNALISATION HEDGEHOG
  申请人：LILLY CO ELI

  公开号：WO2010056588A1

  公开（公告）日：2010-05-20

  The present invention provides novel tetrasubstituted pyridine hedgehog pathway antagonists of the following formula I (I) or a pharmaceutically acceptable salt thereof, wherein: X is C-R1 or N; R1 is hydrogen, fluoro or cyano; R2 is formula II (II), piperidinyl, or gem di-F-substituted cyclohexyl; R3 is methyl or trifluoromethyl; R4 is pyrrolidinyl, morpholinyl or pyridyl, amino or dimethylamino; R5 is trifluoromethyl or methylsulfonyl; R6 is hydrogen or methyl; and R7, R8, R9, R10 and R11 are independently hydrogen fluoro, cyano, chloro, methyl, trifluoromethyl, trifluoromethoxy or methylsulfonyl, provided that al least two of R7, R8, R9, R10 and R11 are hydrogen useful in the treatment of cancer.

  本发明提供了以下式I（I）的新型四取代吡啶刺猬途径拮抗剂或其药学上可接受的盐，其中：X为C-R1或N；R1为氢、氟或氰基；R2为式II（II）、哌啶基或双氟取代的环己基；R3为甲基或三氟甲基；R4为吡咯啉基、吗啉基或吡啶基、氨基或二甲胺基；R5为三氟甲基或甲磺酰基；R6为氢或甲基；以及R7、R8、R9、R10和R11独立地为氢、氟、氰、氯、甲基、三氟甲基、三氟甲氧基或甲磺酰基，但至少两个R7、R8、R9、R10和R11为氢，在癌症治疗中有用。
• Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them
  申请人：Pal Manojit

  公开号：US20060128729A1

  公开（公告）日：2006-06-15

  The present invention provides, among other things, new bicyclo heterocyclic compounds, compositions comprising these heterocyclic compounds, methods of making the heterocyclic compounds, and methods of using these heterocyclic compounds for treating a variety of conditions and disease states associated with, for example, cellular proliferation, inflammation, glycosidase expression, or the low expression of Perlecan.

  本发明提供了新的双环杂环化合物，包括这些杂环化合物的组合物，制备这些杂环化合物的方法，以及利用这些杂环化合物治疗与细胞增殖、炎症、糖苷酶表达或Perlecan低表达等多种疾病状态相关的方法。
• [EN] PHARMACEUTICAL COMPOSITIONS COMPRISING ANTICOAGULANT N-(5-CHLOROPYRIDINE-2-YL)-2-({4-[ETHANIMIDOIL(METHYL)AMINO]BENZOYL}AMINO)-5-METHYLBENZAMIDE<br/>[FR] COMPOSITIONS PHARMACEUTIQUES COMPRENANT UN ANTICOAGULANT N-(5-CHLOROPYRIDIN-2-YL)-2-({4- [ÉTHANIMIDOYL(MÉTHYL)AMINO]BENZOYL}AMINO)-5-MÉTHYLBENZAMIDE
  申请人：PHARMADIALL LTD

  公开号：WO2017217895A1

  公开（公告）日：2017-12-21

  The invention relates to area of medicine, in particular to pharmacology, namely to novel pharmaceutical compositions for oral use for treatment of diseases associated with increased thrombus formation. The compositions comprise the anticoagulant N-(5-chloropyridine-2-yl)-2-(4-[ethanimidoil(methyl)amino]benzoyl}amino)-5-methylbenzamide or a pharmaceutically acceptable salt thereof, being a factor Xa inhibitor and polyprenol, and are protected from the contact with acidic gastric juice by an enteric coating or capsule. The compositions are of high efficacy and bioavailability and can be used to treat and prevent conditions characterized by undesirable thrombosis.

  本发明涉及医学领域，特别是药理学领域，即用于治疗与增加的血栓形成有关的疾病的新型口服药物组合物。该组合物包括抗凝剂N-（5-氯吡啶-2-基）-2-（4- [乙烯基氨基甲酰]氨基}苯甲酰）-5-甲基苯甲酰胺或其药学上可接受的盐，为因子Xa抑制剂和多萜醇，并通过肠溶涂层或胶囊保护不受酸性胃液的接触。该组合物具有高效性和生物利用度，可用于治疗和预防其特征为不良血栓形成的疾病。
• N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
  申请人：John Varghese

  公开号：US20070213316A1

  公开（公告）日：2007-09-13

  Disclosed are compounds of the formula wherein the variables R N , R C , R 1 , R 25 , R 2 , and R 3 are as defined herein. These compounds have activity as inhibitors of beta-secretase and are therefore useful in treating a variety of discorders such as Alzheimer's Disease.

  本发明揭示了以下式子的化合物：其中变量RN，RC，R1，R25，R2和R3如本文所定义。这些化合物具有抑制β-分泌酶的活性，因此可用于治疗多种疾病，例如阿尔茨海默病。